Modulating atherosclerosis through inhibition or blockade of angiotensin

Area of Science:

• Cardiovascular Pharmacology
• Vascular Biology
• Pharmacotherapy

Background:

• Angiotensin-converting enzyme (ACE) inhibitors are established treatments for hypertension, heart failure, and post-myocardial infarction left ventricular dysfunction.
• Angiotensin II type 1 (AT1) receptor blockade has shown cardiovascular benefits in hypertensive patients with left ventricular hypertrophy.
• Emerging evidence suggests ACE inhibitors and ARBs may directly impact the atherosclerotic process.

Purpose of the Study:

• To review the biological mechanisms by which ACE inhibitors and ARBs may modulate atherosclerosis.
• To explore the antiatherogenic properties of these drug classes.
• To highlight the role of angiotensin II in oxidative stress and endothelial dysfunction.

Main Methods:

• Review of existing literature on ACE inhibitors, ARBs, and atherosclerosis.
• Analysis of biochemical pathways involving angiotensin II, oxidative stress, nitric oxide, and bradykinin.
• Synthesis of clinical and preclinical data on the vascular effects of these agents.

Main Results:

• ACE inhibitors and ARBs inhibit angiotensin II, a key mediator of oxidative stress.
• Both drug classes enhance endothelial nitric oxide formation, improving endothelial function.
• ACE inhibitors' vascular effects may also involve bradykinin-mediated mechanisms.

Conclusions:

• ACE inhibitors and ARBs possess antiatherogenic properties through inhibition of angiotensin II and enhancement of endothelial function.
• These mechanisms contribute to cardiovascular protection beyond their established roles in hypertension and heart failure.
• Further research into these pathways may reveal novel therapeutic strategies for atherosclerosis.